Review Article Toxic Oil Syndrome: Review of Immune Aspects of the Disease

REFERENCES

• Abaitua Borda I., Philen R. M., Posada de la Paz M., Gomez de la Camara A., Diez Ruiz-Navarro M., Gimenez Ribota O., Alvargonzalez Soldevilla J., Terracini B., Severiano Pena S., Fuentes Leal C., Kilbourne E. M. Toxic oil syndrome mortality: The first 13 years. Int. J. Epidemiol. 1998; 27: 1057–1063, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Aldridge W. N. The toxic oil syndrome (TOS, 1981): From the disease towards a toxicological understanding of its chemical aetiology and mechanism. Toxicol. Lett. 1992; 64/65: 59–70, [CROSSREF], [CROSSREF]
   Web of Science ®Google Scholar
• Alonso-Ruiz A., Calabozo M., Perez-Ruiz F., Mancebo L. Toxic oil syndrome. A long-term follow-up of a cohort of 332 patients. Medicine (Baltimore) 1993; 72: 285–295
   PubMed Web of Science ®Google Scholar
• Anderson D. E., Halfler D. A. Immune tolerance. Textbook of the Autoimmune Diseases, R. G. Lahita, N. Chiorazzi, W. H. Reeves. Lippincott Williams & Wilkins, Philadelphia 2000; pp. 69–79
   Google Scholar
• Arnaiz-Villena A., Vicario J. L., Serrano-Rios M., Bellas C., Mamposo F. Glomerular basement-membrane antibodies and HLA-DR2 in Spanish rapeseed oil disease. N. Engl. J. Med. 1982; 307: 1404–1405, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Bell S. A. The toxic oil syndrome: An example of an exogenously induced autoimmune reaction. Mol. Biol. Rep. 1996; 23: 261–263, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
   PubMedGoogle Scholar
• Bell S. A., Hobbs M. V., Rubin R. L. Isotype-restricted hyperimmunity in a murine model of the toxic oil syndrome. J. Immunol. 1992; 148: 3369–3376, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Bell S. A., Kuntze I., Caputo A., Chatelain R. Strain-dependent in vitro and in vivo effects of oleic acid anilides on splenocytes and T-cells in a murine model of the toxic oil syndrome. Food Chem. Toxicol. 2002; 40: 19–24, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bell S. A., Sander C., Kuntze I., Chatelain R. The acute pathology of fatty acid anilides and linoleic diester of 3-phenylamino-1,2-propanediol in mice: Possible implication as aetiologic agents for the toxic oil syndrome. Arch Toxicol 1999; 73: 493–495, [PUBMED], [INFOTRIEVE], [CROSSREF], [CROSSREF]
   PubMedGoogle Scholar
• Berking C., Hobbs M. V., Chatelain R., Meurer M., Bell S. A. Strain-dependent cytokine profile and susceptibility to oleic acid anilide in a murine model of the toxic oil syndrome. Toxicol. Appl. Pharmacol. 1998; 148: 222–228, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
   PubMedGoogle Scholar
• Boor P. J., Khan M. F., Kaphalia B. S., Jerrells T. R., Ansari G. A. Synergistic vascular toxicity and fatty acid anilides in the toxic oil syndrome. J. Am. Coll. Cardiol. 1991; 18: 1824–1828, [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Brostoff J., Blanca M., Boulton P., Serrano S. Absence of specific IgE antibodies in toxic oil syndrome. The Lancet 1982; 277, [CROSSREF], [CROSSREF]
   PubMedGoogle Scholar
• Cardaba B., Enzendam J., Gallardo D., del Pozo V., Izquierdo M. M., Martin C., Cortegano M. I., Aceituno E., Rojo M., Arrieta I., Palomino P., Posada de la Paz M., Lahoz C. DR2 antigens are associated with severity of disease in toxic oil syndrome (TOS). Tiss. Antigens 1999; 55: 110–117, [CSA], [CROSSREF], [CROSSREF]
   Google Scholar
• Chen W., Thoburn C. J., Miura Y., Sommer M., Hruban R., Qian Z., Baldwin W., Hess A. D. Autoimmune-mediated vasculopathy. Clin. Immunol. 2001; 100: 57–70, [PUBMED], [INFOTRIEVE], [CROSSREF], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• del Pozo V., de Andres B., Gallardo S., Cardaba B., de Arruda-Chaves E., Cortegano M. I., Jurado A., Palomino P., Oliva H., Aguilera B., Posada M., Lahoz C. Cytokine mRNA expresion in lung tissue from toxic oil syndrome patients: A TH2 immunological mechanism. Toxicology 1997; 118: 61–70, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
   PubMedGoogle Scholar
• Gallardo S., Cardaba B., del Pozo V., Belen d. A., Cortegano M. I., Jurado A., Tramon P., Palomino P., Lahoz C. Study of apoptosis in human lymphocytes by toxic substances implicated in toxic oil syndrome. Toxicology 1997; 118: 71–82, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
   PubMedGoogle Scholar
• Gallardo S., del Pozo V., Cardaba B., de Andres B., Martin-Orozco E., Fernandez J. C., Tramon P., Posada de la Paz M., Abaitua Borda I., Palomino P., Lahoz C. Immunological basis of toxic oil syndrome (TOS). Toxicology 1994; 93: 289–299, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Gelpi E., Posada de la Paz M., Terracini B., Abaitua I., Gomez de la Camara A., Kilbourne E. M., Lahoz C., Nemery B., Philen R. M., Soldevilla L., Tarkowski S. The Spanish toxic oil syndrome 20 years after its onset: A multidisciplinary review of scientific knowledge. Environmental Health Perspectives 2002; 110: 457–464, [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Gomez D., Correa P. A., Gomez L. M., Cadena J., Molina J. F., Anaya J. M. TH1/TH2 cytokines in patients with systemic lupus erythematosus: Is tumor necrosis factor alpha protective?. Semin. Arthritis Rheum. 2004; 33: 404–413, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Gomez de la Camara A., Abaitua Borda I., Posada de la Paz M. Toxiocologists versus toxicological disasters: Toxic oil syndrome, clinical aspects. Applied Toxicology: Approaches Through Basic Sciences, J. P. Seiler, E. Vilanova. Springer, Berlin Heidelberg 1997; pp. 31–40
   Google Scholar
• Hard G. C. Short-term adverse effects in humans of ingested mineral oils, their additives, and possible contaminants—a review. Human and Experimental Toxicology 2000; 19: 158–172, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Hard G. C. A search for an animal model of the Spanish toxic oil syndrome. Food Chem. Toxicol. 2002; 40: 1551–1567, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
   PubMedGoogle Scholar
• Hein D. W. Molecular genetics and function on NAT1 and NAT 2: Role in aromatic amine metabolism and carcinogenesis. Mutat. Res. 2002; 506–507: 65–77
   PubMed Web of Science ®Google Scholar
• Hill R. H., Jr., Schurz H. H., Posada de la Paz M., Abaitua Borda I., Philen R. M., Kilbourne E. M., Head S. L., Bailey S. L., Driskell W. J., Barr J. R. Possible etiologic agents for toxic oil syndrome: Fatty acid esters of 3-(n-phenylamino)-1,2-propanediol. Arch. Environ. Contam. Toxicol. 1995; 28: 259–264, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
   PubMedGoogle Scholar
• Jacobson D. L., Gange S. J., Rose N. R., Graham N. M. H. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin. Immunol. Immunopath. 1997; 84: 223–243, [CSA], [CROSSREF], [CROSSREF]
   PubMedGoogle Scholar
• Kallmann B. A., Huther M., Tubes M., Feldkamp J., Bertrams J., Gries F. A., Lampeter E. F., H., K. Systemic bias of cytokine production toward cell-mediated immune regulation in IDDM and toward humoral immunity in Graves' Disease. Diabetes 1997; 46: 237–243, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Kammuller M. E., Bloksma N., Seinen W. Chemical-induced autoimmune reactions and Spanish toxic oil syndrome. Focus on hydantions and related compounds. Clin. Toxicol. 1988; 26: 157–174
   Google Scholar
• Kaufman L., Krupp L. Eosinophilia-myalgia syndrome, toxic-oil syndrome, and diffuse fasciitis with eosinophilia. Curr. Opin. Rheumatol. 1995; 7: 560–567, [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Kaufman L. D., Izquierdo Martinez M., Serrano J. M., Gomez-Reino J. J. 12-Year follow-up study of epidemic Spanish toxic oil syndrome. J. Rheumatol. 1995; 22: 282–288, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Khan M. F., Kaphalia B. S., Ansari G. A. Heated linoleic acid anilide reduces serum enzyme activities in rats. Res. Commun. Chem. Pathol. Pharmacol. 1991a; 73: 107–110, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Khan M. F., Kaphalia B. S., Palafox A., Jerrells T. R., Ansari G. A. Heated linoleic acid anilide: Toxicity and relevance to toxic oil syndrome. Toxicology 1991b; 68: 143–155, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Koeger A., Lang T., Alcaix D., Milleron B., Rozenberg S., Chaibi P., Arnaud J., Mayaud C., Camus J., Bourgeois P. Silica-associated connective tissue disease. A study of 24 cases. Medicine (Baltimore) 1995; 74: 221–237, [CSA], [CROSSREF], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Koller L. D., Stang B. V., Hall J. A., Posada de la Paz M., Ruiz-Mendez M. V. Immunoglobulin and autoantibody responses in MRL/lpr mice treated with “toxic oils.”. Toxicology 2002; 178: 119–133, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Koller L. D., Stang B. V., Posada de la Paz M., Ruiz-Mendez M. V. Pathology of “toxic oils” and selected metals in the MRL/lpr mouse. Toxicol. Pathol. 2001; 29: 630–638, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
   PubMedGoogle Scholar
• Ladona M. G., Izquierdo Martinez M., Posada de la Paz M., de la Torre R., Ampurdanes C., Segura J., Sanz E. J. Pharmacogenetic profile of xenobiotic enzyme metabolism in survivors of the Spanish toxic oil syndrome. Environ. Health Perspect. 2001; 109: 369–375, [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Lahoz C., del Pozo V., Gallardo S., Cardaba B., Jurado A., Cortegano M. I., del Amo A., Arrieta I., Palomino P. Immunological aspects of the toxic oil syndrome. Applied Toxicology: Approaches Through Basic Science, J. P. Seiler, E. Vilanova. Springer, Berlin Heidelberg 1997; pp. 63–73
   Google Scholar
• Mavalia C., Scalettei C., Romagnani P., Carossino A. M., Pignone A., Emmi L., Pupilli C., Pizzolo G., Maggi E., Romagnani S. Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis. Am. J. Pathol. 1997; 151: 1751–1758, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Moller E. Mechanisms for induction of autoimmunity in humans. Acta Paediatr. Suppl. 1998; 424: 16–20, [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Philen R. M., Posada de la Paz M., Hill R. H., Schurz H. H., Abaitua Borda I., Gomez de la Camara A., Kilbourne E. M. Epidemiology of the Toxic Oil Syndrome. Berlin Heidelberg 1997
   Google Scholar
• Posada de la Paz M., Abaitua Borda I., Kilbourne E. M., Tabuenca Oliver J., Diaz de Rojas F., Castro Garcia M. Late cases of toxic oil syndrome: Evidence that the aetiological agent persisted in oil stored for up to one year. Food Chem. Toxicol. 1989; 27: 517–521, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
   PubMedGoogle Scholar
• Posada de la Paz M., Philen R. M., Abaitua Borda I., Sicilia Socias J. M., Gomez de la Camara A., Kilbourne E. M. Toxic oil syndrome: Traceback of the toxic oil and evidence for a point source epidemic. Food Chem. Toxicol. 1996; 34: 251–257, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Quero C., Colome N., Prieto M. R., Carrascal M., Posada de la Paz M., Gelpi E., Abian J. Determination of protein markers in human serum: Analysis of protein expression in toxic oil syndrome studies. Proteomics 2004; 4: 303–315, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
   PubMedGoogle Scholar
• Rao T., Richardson B. Environmentally-induced autoimmune diseases: Potential mechanisms. Environmental Health Perspectives 1999; 107: 737–742, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Ruiz-Mendez M., Posada de la Paz M., Abian J., Calaf R., Blount B., Castro-Molero N., Philen R. M., Gelpi E. Storage time and deodorization temperature influence the formation of aniline-derived compounds in denatured rapeseed oils. Food Chem. Toxicol. 2001; 39: 91–96, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
   PubMedGoogle Scholar
• Ruschpler R., Stiehl P. Shift in TH1 (Il-2 and IFN-γ) and TH2 (Il-10 and Il-4) cytokine mRNA balance within two new histological main-types of rheumatoid arthritis (RA). Cell. Mol. Biol. 2002; 48: 285–293, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Sanchez-Porro Valades P., Posada de la Paz M., de Andres Copa P., Gimenez Ribota O., Abaitua Borda I. Toxic oil syndrome: Survival in the whole cohort between 1981 and 1995. J. Clin. Epidemiol. 2003; 56: 701–708, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Schurz H. H., Hill R. H., Philen R. M., Posada de la Paz M., Abaitua Borda I., Kilbourne E. M., Bernert T., Needham L. L. Analytical measurements of products of aniline and triglycerides in oil samples associated with the toxic oil syndrome. Applied Toxicology: Approaches Through Basic Science, J. P. Seiler, E. Vilanova. Springer, Berlin Heidelberg 1997; pp. 53–63
   Google Scholar
• Serrano-Mollar A., Fernandez-Zabalegui L., Bulbena O., Gelpi E., Closa D. Induction of c-fos messenger RNA by 3-(N-phenylamino)-1,2-propanediol esters, compounds related to toxic oil syndrome. Chem.-Biol. Inteact. 2004; 149: 117–123, [CSA], [CROSSREF], [CROSSREF]
   PubMedGoogle Scholar
• Straus S., Sneller M., Lenardo M., Puck J., Strober W. An inheritied disorder of lymphocyte apoptosis: The autoimmune lymphoproliferative syndrome. Ann. Intern. Med. 1999; 130: 591–601, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Tabuenca J. M. Toxic-allergic syndrome caused by ingestion of rapeseed oil denatured with aniline. The Lancet 1981; 2: 567–568, [CROSSREF], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Thomas T. Effects of lupus-inducing drugs on the b to z transition of synthetic DNA. Arthritis Rheum. 1986; 29: 638–645, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Tomer Y., Barak V., Gilburd B., Shoenfeld Y. Cytokines in experimental autoimmune vasculitis: Evidence for a TH2 type response. Clin. Exp. Rheumatol. 1999; 17: 521–526, [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Vicario J. L., Serrano-Rios M., San Andres F., Arnaiz-Villena A. HLA-DR3, DR4 increase in chronic stage of Spanish oil disease. The Lancet 1982; 276
   Google Scholar
• Weatherhill A. R., Stang B. V., O'Hara K., Koller L. D., Hall J. A. Investigating the onset of autoimmunity in As.W mice following treatment with ‘toxic oils.’. Toxicol. Lett. 2003; 136: 205–216, [CSA], [CROSSREF], [CROSSREF]
   PubMedGoogle Scholar
• Wulferink M., Gonzalez J., Goebel C., Gleichmann E. T-Cells ignore aniline, a prohapten, but respond to its reactive metabolites generated by phagocytes: Possible implications for the pathogenesis of toxic oil syndrome. Chem. Res. Toxicol. 2001; 14: 389–397, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Zhang Z. Y., Michael J. G. Orally inducible immune unresponsiveness is abrogated by IFN-γ treatment. J. Immunol. 1990; 144: 4163–4165, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar